Mesoblast (MESO) Announces Positive Data from MPC-300-IV Phase 2 in RA

Phase 2 Trial Results of Mesoblast’s Cell Therapy Show Dose-Related Improvements in Biologic Refractory Rheumatoid Arthritis

August 8, 2016 7:12 PM EDT

Key points:

The biologic refractory rheumatoid arthritis (RA) population accounts for approximately one-third of all RA patients who have received anti-TNF or other biologic agents, is the fastest growing branded market segment, the hardest to treat, and requires new therapies that are both effective and safeIntravenous infusions of allogeneic Mesenchymal Precursor Cells (MPCs) were well tolerated in biologic refractory RA patients and were without serious adverse events over 12 weeksA single intravenous MPC infusion in biologic refractory RA patients resulted in dose-related improvements in clinical symptoms, function, and disease activity, with the... More